Product
SARS-CoV-2 rS antigen + Matrix-M Adjuvant
Aliases
SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Updated Novavax COVID-19 vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of AgeStatus: Completed, Estimated PCD: 2023-11-11